Analyzing the Metrics of Stocks Advertised on CNBC
Looking into some of the companies advertised on CNBC shows their riskiness for stock investors.
Charles Rotblut
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Looking into some of the companies advertised on CNBC shows their riskiness for stock investors.
Charles Rotblut
| Share Statistics | CANF | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $5.0 | $213.9 | 5% |
|
| Shares Out (Mil) | 3.7 | 55.4 | 12% |
|
| Institutional Ownership | 100.0% | 93.3% | 99% |
|
| Float (Mil) | 6.1 | 40.6 | 14% |
|
| Beta | -0.04 | 0.98 | 4% |
|
| Avg Daily Volume (000s) | 41 | 597 | 27% |
|
| Price Change (52-week) |
(79.1%) | 40.9% | 9% |
|
| Growth | CANF | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (12.9%) | 13.2% | 4% |
|
| Net Income (5yr) | 7.4% | (10.7%) | 51% |
|
| EPS (5yr) | 45.7% | 15.5% | 91 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (60.8%) | (15.7%) | 4% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | CANF | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $0 | $39 | 1% |
|
| Net Income (TTM) (Mil) | ($10) | ($44) | 29% |
|
| EPS (TTM) | ($3.257) | ($1.400) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($10) | ($34) | 21% |
|
| Net Cash Flow (TTM) (Mil) | ($4) | $-0 | 38% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($2) | $135 | 4% |
|
| Valuation | CANF | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.34 | 1.97 | 40% |
|
| P/E | na | 17.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | CANF | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 67.9% | 96% |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (121.1%) | (47.5%) | 4% |
|
| ROE | (211.4%) | (51.9%) | 4% |
|
| Liabilities to Assets | 39.7% | 29.7% | 30% |
|
| F-Score | 3 | 3 | 18% |
|
Can-Fite BioPharma Ltd. did not pass any screens on 11/18/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors